156 related articles for article (PubMed ID: 34297268)
1. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Bockorny B; Bullock AJ; Abrams TA; Faintuch S; Alsop DC; Goldberg SN; Ahmed M; Miksad RA
Dig Dis Sci; 2022 Jul; 67(7):3455-3463. PubMed ID: 34297268
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Fukuda H; Numata K; Moriya S; Shimoyama Y; Ishii T; Nozaki A; Kondo M; Morimoto M; Maeda S; Sakamaki K; Morita S; Tanaka K
Radiology; 2014 Aug; 272(2):598-604. PubMed ID: 24689883
[TBL] [Abstract][Full Text] [Related]
3. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Tang Z; Kang M; Zhang B; Chen J; Fang H; Ye Q; Jiang B; Wu Y
Tumori; 2017 May; 103(3):286-291. PubMed ID: 28058713
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib after RFA in HCC patients: a pilot study.
de Stefano G; Farella N; Scognamiglio U; Liorre G; Calabria G; Ascione T; Giorgio A; Iodice V
Hepatogastroenterology; 2015; 62(138):261-3. PubMed ID: 25916044
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study.
Lassandro G; Picchi SG; Bianco A; Di Costanzo G; Coppola A; Ierardi AM; Lassandro F
Med Oncol; 2020 Mar; 37(4):25. PubMed ID: 32166529
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
Zhou Q; Wang X; Li R; Wang C; Wang J; Xie X; Li Y; Li S; Mao X; Liang P
J Gastroenterol; 2022 Sep; 57(9):684-694. PubMed ID: 35816221
[TBL] [Abstract][Full Text] [Related]
11. Radiofrequency ablation combined with chemoembolization for intermediate-sized (3-5 cm) hepatocellular carcinomas under dual guidance of biplane fluoroscopy and ultrasonography.
Min JH; Lee MW; Cha DI; Jeon YH; Shin SW; Cho SK; Rhim H; Lim HK
Korean J Radiol; 2013; 14(2):248-58. PubMed ID: 23483753
[TBL] [Abstract][Full Text] [Related]
12. Fusion of Preinterventional MR Imaging With Liver Perfusion CT After RFA of Hepatocellular Carcinoma: Early Quantitative Prediction of Local Recurrence.
Kobe A; Kindler Y; Klotz E; Puippe G; Messmer F; Alkadhi H; Pfammatter T
Invest Radiol; 2021 Mar; 56(3):188-196. PubMed ID: 32932379
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Li Y; Zheng YB; Zhao W; Liu B; Hu BS; He X; Huang JW; Lu LG
Med Oncol; 2013 Dec; 30(4):730. PubMed ID: 24048774
[TBL] [Abstract][Full Text] [Related]
14. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
[TBL] [Abstract][Full Text] [Related]
16. Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial).
Chong CCN; Lee KF; Cheung SYS; Chu CCM; Fong AKW; Wong J; Hui JWY; Fung AKY; Lok HT; Lo EYJ; Chan SL; Yu SCH; Ng KKC; Lai PBS
HPB (Oxford); 2020 Aug; 22(8):1121-1127. PubMed ID: 32044268
[TBL] [Abstract][Full Text] [Related]
17. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
18. The Efficacy and Therapeutic Outcome of Bipolar Radiofrequency Ablation for the Treatment for Hepatocellular Carcinoma in the Real-World Setting, Compared with Monopolar Radiofrequency Ablation Conducted during the Same Period.
Tanaka T; Takata K; Kunimoto H; Fukuda H; Yamauchi R; Tsuchiya N; Inomata S; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Oncology; 2020; 98(12):859-868. PubMed ID: 32799203
[TBL] [Abstract][Full Text] [Related]
19. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma.
Lin CC; Lui KW; Chen WT; Hsieh YC; Cheng YT; Teng W; Lin SM
Eur Radiol; 2021 Nov; 31(11):8649-8661. PubMed ID: 33895858
[TBL] [Abstract][Full Text] [Related]
20. The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis.
Qu C; Li XQ; Li C; Xia F; Feng K; Ma K
J Invest Surg; 2022 Apr; 35(4):880-887. PubMed ID: 34085878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
